Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7474281 | 0.81 | CYP2C9 (0.38) | CYP3A4CYP2C9CYP2C19POLBALDH1A1 | |
| SCHEMBL8961381 | 0.81 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL8800000 | 0.81 | POLB (0.43) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL27816008 | 0.79 | CYP3A4 (0.42) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL9067967 | 0.78 | ALDH1A1 (0.41) | CYP3A4CYP2C9CYP2C19POLBALDH1A1 | |
| SCHEMBL10108 | 0.77 | GAA (0.40) | CYP3A4CYP2C9CYP2C19POLBALDH1A1 | |
| SCHEMBL426906 | 0.77 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19POLBALDH1A1 | |
| SCHEMBL3623284 | 0.76 | CYP3A4 (0.37) | CYP3A4CYP2C9CYP2C19POLBALDH1A1 | |
| SCHEMBL9377677 | 0.75 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19POLBALDH1A1 | |
| SCHEMBL365852 | 0.75 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570618-B2 | Compound, production method therefor, and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2026-03-10 | — | — | US | disclosed |
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4293013-B1 | NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION | UNIV TOKYO SCIENCE FOUND (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-07-10 | — | — | US | disclosed |
| WO-2025011494-A1 | CRYSTAL FORM OF PIPERAZINO RING-CONTAINING DERIVATIVE, SALT FORM, PREPARATION METHOD, AND USE | 优领医药科技(香港)有限公司 | 2025-01-16 | — | — | WO | disclosed |
| EP-4464704-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Acerand Therapeutics (Hong Kong) Limited (HK) | 2024-11-20 | — | — | EP | disclosed |
| EP-4434985-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-118055933-A | Selective PARP1 inhibitors and uses thereof | 成都百裕制药股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240140918-A1 | NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION | NATIONAL CANCER CENTER (JP) | 2024-05-02 | — | — | US | disclosed |
| EP-4293013-A1 | NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022222965-A1 | PYRIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022172786-A1 | NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION | 学校法人東京理科大学 | 2022-08-18 | — | — | WO | disclosed |
| WO-2022052924-A1 | PREPARATION METHOD FOR CLASS OF NITROGEN-CONTAINING FUSED RING COMPOUNDS AND USE THEREOF | 上海凌达生物医药有限公司 | 2022-03-17 | — | — | WO | disclosed |
| EP-0790994-B1 | HETEROCYCLE SUBSTITUTED PROPENOIC ACID DERIVATIVES AS NMDA ANTAGONISTS | AVENTIS PHARMA INC (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6372943-B1 | COMPOUNDS ORIGINATING FROM NATURAL PRODUCTS WHICH EXHIBIT EXCELLENT DISPERSING ABILITY, MASK INTERFERING METAL IONS BY CHELATING WITH THEM, AND POSSESS SURFACE ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| US-6180786-B1 | ANTAGONIST FOR EXCITORY AMINO ACIDS | HOECHST MARION ROUSSEL, INC. | 2001-01-30 | — | — | US | disclosed |
| EP-1063223-A1 | POLYENEPOLYCARBOXYLIC ACIDS, DERIVATIVES THEREOF WITH RESPECT TO CARBOXYL GROUPS, OR SALTS OF THESE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-5981553-A | BLOCKING EXCITATORY AMINO ACID ACTION IN PREVENTING HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, SENILE DEMENTIA, GLUTARIC ACIDAEMIA TYPE I, MULTI-INFARCT DEMENTIA, AMYOTROPHIC LATERAL SCLEROSIS OR NEURONAL DAMAGE FROM SEIZURES | HOECHST MARION ROUSSEL, INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5563157-A | EXCITATORY AMINO ACID ANTAGONISTS | HOECHST MARION ROUSSEL INC. (US) | 1996-10-08 | — | — | US | disclosed |
| US-5519048-A | 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof | MERRELL PHARMACEUTICALS INC. (US) | 1996-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PARP1, PARP11, PARP15 | CYP3A4 2278/4885CYP2C9 3446/4885CYP2C19 1049/4885 |
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | PARP1, PARP11, PARP12 | CYP3A4 3261/4885CYP2C9 4093/4885CYP2C19 2431/4885 |
| US-20240140918-A1 | NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION | CYP4F11, RTRAF, MRPS18A | CYP3A4 283/4885CYP2C9 321/4885CYP2C19 764/4885 |
| US-12570618-B2 | Compound, production method therefor, and pharmaceutical composition | DHCR7, NR1H3, NR1H2 | CYP3A4 105/4885CYP2C9 129/4885CYP2C19 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.